Towards the discovery of novel T-type calcium channel blockers

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 5, 2007, Pages 717-722

  Lory, Philippe ^a   Chemin, Jean ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Cav3 subunit; Low voltage activated; T type calcium channel

Indexed keywords

AMILORIDE; ANANDAMIDE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CALCIUM CHANNEL T TYPE BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; ETHOSUXIMIDE; FLUNARIZINE; FLUOXETINE; FLUSPIRILENE; HALOPERIDOL; KURTOXIN LIKE 1 PROTEIN; KURTOXIN LIKE 2 PROTEIN; LIPID; MESUXIMIDE; MIBEFRADIL; NEUROLEPTIC AGENT; NICKEL; PENFLURIDOL; PHENYTOIN; PIMOZIDE; SCORPION VENOM; SIPATRIGINE; SUCCINIMIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ZINC ION;

ABSENCE; ANESTHESIA MECHANISM; AUTISM; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; DEPRESSION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; HEART ARRHYTHMIA; HUMAN; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN FUNCTION; REVIEW;

ANALGESICS; ANIMALS; ANTICONVULSANTS; ARACHIDONIC ACIDS; AUTISTIC DISORDER; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CATIONS; DRUG DESIGN; EPILEPSY; HUMANS; MICE; MICE, KNOCKOUT; POLYUNSATURATED ALKAMIDES; SCORPION VENOMS; SLEEP DISORDERS, INTRINSIC;

EID: 34248399087     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.5.717     Document Type: Review

References (61)

1. HUGUENARD JR: Low-threshold calcium currents in central nervous system neurons. Ann. Rev. Physiol. (1996) 58:329-348.
2. PEREZ-REYES E: Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev. (2003) 83:117-161.
3. YUNKER AM, MCENERY MW: Low-voltage-activated ('T Type') calcium channels in review. J. Bioenerg. Biomembr. (2003) 35:533-575.
4. LACINOVA L: Voltage-dependent calcium channels. Gen. Physiol. Biophys. (2005) 24(Suppl. 1):1-78.
5. NILIUS B, TALAVERA K, VERKHRATSKY A: T-type calcium channels: the never ending story. Cell Calcium (2006) 40:81-88.
6. 2+ channels. Neuron (2001) 31:35-45.
7. 2+ channels. Science (2003) 302:1416-1418.
8. 2+ channels. Science (2003) 302:117-119.
9. 2+ channel plays a crucial role in stabilizing sleep. Proc. Natl. Acad. Sci. USA (2005) 102:1743-1748.
10. v3.1/ α1G T-type calcium channels. Circ. Res. (2006) 98:1422-1430.
11. 2+ channels by Ro 40-5967. Circ. Res. (1994) 75:144-148.
12. CLOZEL JP, ERTEL EA, ERTEL SI: Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J. Hypertens. (1997) 15(Suppl.)S17-S25.
13. LACINOVA L: Pharmacology of recombinant low-voltage activated calcium channels. Curr. Drug Targets CNS Neurol. Disord. (2004) 3:105-111.
14. BEEDLE AM, HAMID J, ZAMPONI GW: Inhibition of transiently expressed low- and high-voltage-activated calcium channels by trivalent metal cations. J. Membr. Biol (2002) 187:225-238.
15. LEE JH, GOMORA JC, CRIBBS LL, PEREZ-REYES E: Nickel block of three cloned T-type calcium channels: low concentrations selectively block α1H. Biophys. J. (1999) 77:3034-3042.
16. 2+ channels and pharmacological blockade: potential pathophysiological relevance. Cardiovasc. Drugs Ther. (1997) 11:723-739.
17. PO AL, ZHANG WY: What lessons can be learnt from withdrawal of mibefradil from the market? Lancet (1998) 351:1829-1830.
18. LEURANGUER V, MANGONI ME, NARGEOT J, RICHARD S: Inhibition of T-type and L-type calcium channels by mibefradil: physiologic and pharmacologic bases of cardiovascular effects. J. Cardiovasc. Pharmacol. (2001) 37:649-661.
19. v1.2. Circ. Res. (2006) 98:105-110.
20. GACKIERE F, BIDAUX G, LORY P, PREVARSKAYA N, MARIOT P: A role for voltage gated T-type calcium channels in mediating 'capacitative' calcium entry? Cell Calcium (2006) 39:357-366.
21. TANG CM, PRESSER F, MORAD M: Amiloride selectively blocks the low threshold (T) calcium channel. Science (1988) 240:213-215.
22. TYTGAT J, VEREECKE J, CARMELIET E: Mechanism of cardiac T-type Ca channel blockade by amiloride. J. Pharmacol. Exp. Ther. (1990) 254:546-551.
23. WILLIAMS ME, WASHBURN MS, HANS M et al.: Structure and functional characterization of a novel human low-voltage activated calcium channel. J. Neurochem. (1999) 72:791-799.
24. MONTEIL A, CHEMIN J, BOURINET E, MENNESSIER G, LORY P, NARGEOT J: Molecular and functional properties of the human α1G subunit that forms T-type calcium channels. J. Biol. Chem. (2000) 275:6090-6100.
25. 2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J. Neurophysiol (1998) 79:240-252.
26. 2+ current of mouse spermatogenic cells. Mol. Pharmacol. (1998) 53:1104-1111.
27. BERTHIER C, MONTEIL A, LORY P, STRUBE C: α1H mRNA in single skeletal muscle fibres accounts for T-type calcium current transient expression during fetal development in mice. J. Physiot. (2002) 539:681-691.
28. AKAIKE N: T-type calcium channel in mammalian CNS neurones. Comp. Biochem. Physiol. C. (1991) 98:31-40.
29. SANTI CM, CAYABYAB FS, SUTTON KG et al.: Differential inhibition of T-type calcium channels by neuroleptics. J. Neurosci. (2002) 22:396-403.
30. RICHELSON E, SOUDER T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. (2000) 68:29-39.
31. 2+ channels is an important action of succinimide antiabsence drugs. Epilepsy Curr. (2002) 2:49-52.
32. 2+ channels by ethosuximide is not the whole story. Epilepsy Curr. (2002) 2:53-56.
33. 2+ channel currents. Eur. J. Pharmacol. (2003) 467:77-80.
34. v3.2 channel is a molecular substrate for inhibition of T-type calcium currents in rat sensory neurons by nitrous oxide. Mol. Pharmacol. (2001) 60:603-610.
35. TODOROVIC SM, PEREZ-REYES E, LINGLE CJ: Anticonvulsants but not general anesthetics have differential blocking effects on different T-type current variants. Mol. Pharmacol. (2000) 58:98-108.
36. TRABOULSIE A, CHEMIN J, KUPFER E, NARGEOT J, LORY P: T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol. Pharmacol. (2006) 69:1963-1968.
37. CHUANG RS, JAFFE H, CRIBBS L, PEREZ-REYES E, SWARTZ KJ: Inhibition of T-type voltage-gated calcium channels by a new scorpion toxin. Nat. Neurosci. (1998) 1:668-674.
38. SIDACH SS, MINTZ IM: Kurtoxin, a gating modifier of neuronal high- and low-threshold ca channels. J. Neurosci. (2002) 22:2023-2034.
39. + channels. Biochem. Biophys. Res. Commun. (2002) 299:562-568.
40. DI MARZO V, DE PETROCELLIS L, BISOGNO T: The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb. Exp. Pharmacol. (2005) 168:147-185.
41. CHEMIN J, MONTEIL A, PEREZ-REYES E, NARGEOT J, LORY P: Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J (2001) 20:7033-7040.
42. CHEMIN J, NARGEOT J, LORY P: Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J. Biol. Chem. (2007) 282:2314-2323.
43. DANTHI SJ, ENYEART JA, ENYEART JJ: Modulation of native T-type calcium channels by omega-3 fatty acids. Biochem. Biophys. Res. Commun. (2005) 327:485-493.
44. 2+ channel α1G. J. Gen. Physiol. (2004) 124:225-238.
45. MATHIE A, SUTTON GL, CLARKE CE, VEALE EL: Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. Pharmacol. Ther. (2006) 111:567-583.
46. 2+) blocks voltage gated calcium channels in cultured rat dorsal root ganglion cells. Brain Res. (1992) 593:77-8 1.
47. JEONG SW, PARK BG, PARK JY, LEE JW, LEE JH: Divalent metals differentially block cloned T-type calcium channels. Neuroreport (2003) 14:1537-1540.
48. TRABOULSIE A, CHEMIN J, CHEVALIER M, QUIGNARD JF, NARGEOT J, LORY P: Subunit-specific modulation of T-type calcium channels by zinc. J. Physiol. (2007) 578:159-171.
49. DODDAREDDY MR, JUNG HK, LEE JY et al.: First pharmacophoric hypothesis for T-type calcium channel blockers. Bioorg. Med. Chem. (2004) 12:1605-1611.
50. CHOI JY, SEO HN, LEE MJ et al.: Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg. Med. Chem. Lett. (2007) 17:471-475.
51. DODDAREDDY MR, CHOO H, CHO YS et al.: 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem (2007) 15:1091-1105.
52. PARK JH, CHOI JK, LEE E et al.: Lead discovery and optimization of T-type calcium channel blockers. Bioorg. Med. Chem. (2007) 15:1409-1419.
53. HUANG L, KEYSER BM, TAGMOSE TM et al.: NNC 55-0396 [(1S,2S)-2-(2-(N-[(3-benzimidazol-2-yl) propyl]-N-methylamino)ethyl)-6-fluo ro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride]: a new selective inhibitor of T-type calcium channels. J. Pharmacol. Exp. Ther. (2004) 309:193-199.
54. AKAIKE N, KOSTYUK PG, OSIPCHUK YV: Dihydropyridine-sensitive low-threshold calcium channels in isolated rat hypothalamic neurones. J. Physiol (1989) 412:181-195.
55. GODFRAIND T: Calcium-channel modulators for cardiovascular disease. Expert Opin. Emerg. Drugs (2006) 11:49-73.
56. KUMAR PP, STOTZ SC, PARAMASHIVAPPA R, BEEDLE AM, ZAMPONI GW, RAO AS: Synthesis and evaluation of a new class of nifedipine analogs with T-type calcium channel blocking activity. Mol. Pharmacol. (2002) 61:649-658.
57. TANAKA H, KOMIKADO C, SHIMADA H et al.: The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium. J. Pharmacol. Sci. (2004) 96:499-501.
58. 2+ channel (α1G) expressed in Xenopus oocytes. J. Cardiovasc. Pharmacol. (2005) 45:241-246.
59. MCGIVERN JG: Pharmacology and drug discovery for T-type calcium channels. CNS Neurol. Disord. Drug Targets (2006) 5:587-603.
60. BIDAUD I, MEZGHRANI A, SWAYNE LA, MONTEIL A, LORY P: Voltage-gated calcium channels in genetic diseases. Biochim. Biophys. Acta (2006) 1763:1169-1174.
61. CHEMIN J, TRABOULSIE A, LORY P: Molecular pathways underlying the modulation of T-type calcium channels by neurotransmitters and hormones. Cell Calcium (2006) 40:121-134.